- You can view the full Pfizer Ratings Report.
The Dow Jones Industrial Average ( ^DJI) is trading up 110 points (+0.8%) at 13,069 as of Tuesday, Mar 13, 2012, 12:39 p.m. ET. During this time, 310.4 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio sits at 2,270 issues advancing vs. 706 declining with 83 unchanged. The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting a 39-cent gain (+1.8%) bringing the stock to $21.93. This single gain is lifting the Dow Jones Industrial Average by 2.95 points or roughly accounting for 2.7% of the Dow's overall gain. Volume for Pfizer currently sits at 20.5 million shares traded vs. an average daily trading volume of 43.5 million shares. Pfizer has a market cap of $166.5 billion and is part of the health care sector and drugs industry. Shares are down 0.5% year to date as of Monday's close. The stock's dividend yield sits at 4.1%. Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 19.4, above the average drugs industry P/E ratio of 14.9 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.